false
0000946563
0000946563
2026-03-27
2026-03-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
| Date
of Report (Date of earliest event reported) |
March 27, 2026 |
Retractable Technologies, Inc.
(Exact name of registrant
as specified in its charter)
| Texas |
001-16465 |
75-2599762 |
| (State or other jurisdiction |
(Commission |
(IRS Employer |
| of incorporation) |
File Number) |
Identification No.) |
| 511
Lobo Lane, Little
Elm, Texas |
75068-5295 |
| (Address of principal executive
offices) |
(Zip Code) |
| Registrant's
telephone number, including area code |
(972)
294-1010 |
None
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock |
RVP |
NYSE
American |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| |
Emerging
growth company ¨ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On March 27, 2026, the
Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99.1, announcing results for 2025.
On March 27, 2026, the
Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99.2, announcing the declaration of
a dividend to the Series II and Series III Class B Convertible Preferred Stock shareholders.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 | Press release announcing results for 2025. |
| 99.2 | Press release announcing the declaration of a dividend to the Series II and Series III Class B
Convertible Preferred Stock shareholders. |
| 104 | Cover Page Interactive Date File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| DATE: March 27, 2026 |
RETRACTABLE TECHNOLOGIES, INC. |
| |
(Registrant) |
| |
|
|
| |
BY: |
/s/ JOHN W. FORT III |
| |
|
JOHN W. FORT III |
| |
|
VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER |
Exhibit 99.1
RETRACTABLE TECHNOLOGIES, INC. REPORTS
RESULTS FOR 2025
LITTLE ELM, Texas, March 27, 2026—Retractable
Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further
details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 27,
2026 with the U.S. Securities and Exchange Commission.
The Company’s revenues for 2025 increased
15.8%. The Company’s revenues were approximately $38.3 million in 2025 as compared to approximately $33.0 million in the prior
year. Domestic revenues increased 9.7% principally due to an increase in VanishPoint® and EasyPoint®
needle sales. International revenues increased 64.0% predominantly due to higher EasyPoint® needle sales. Comparability
of 2025 to 2020-2023 financial results is challenging due to the unusual volume of pandemic sales in those years.
The Company’s operating costs remain high
since its facility expansion and, more recently, an increase in domestic production in connection with 2024-2026 tariffs. Total
operating expenses were $21.2 million in 2025. The 2025 loss from operations was $21.2 million as compared to a loss from operations
of $21.1 million in the prior year.
The net decrease in cash for 2025 was $1.6 million.
At the end of 2025, the Company’s cash position was $2.6 million, and the Company held $34.4 million in debt and equity securities.
Approximately $1.8 million was incurred in tariff
expense in 2025. The Company obtained 62.6% of its products from manufacturers in China. As of March 9, 2026, the prevailing
tariff rate on most syringe and needle products imported from China was 120%. As foreign trade policy continues to evolve, uncertainty
as to future tariff rates remains. Management expects that tariffs will continue to have a material impact on the Company’s operations
and financial position.
ABOUT RETRACTABLE
Retractable manufactures and markets VanishPoint®
and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe,
blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly
from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed
to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable
needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint®
needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general
line distributors.
For more information on Retractable, visit its
website at www.retractable.com.
Forward-looking statements in this press release
are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current
views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate.
However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from
such statements.
Factors that could cause or contribute to such
differences include, but are not limited to: tariffs; material changes in demand, Retractable's ability to maintain liquidity; Retractable's
maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and
relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in
providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic
reports filed with the U.S. Securities and Exchange Commission.
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief
Accounting Officer
Exhibit 99.2
RETRACTABLE TECHNOLOGIES, INC. DECLARES
DIVIDENDS TO SERIES II AND III CLASS B PREFERRED STOCK SHAREHOLDERS
LITTLE ELM, Texas, March 27, 2026 —
Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared
dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of
$39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning
January 1, 2026 through March 31, 2026. The dividends will be paid on April 20, 2026 to shareholders of record as of the
close of business on April 10, 2026.
Retractable manufactures and markets VanishPoint®
and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe,
blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly
from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed
to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable
needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint®
needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general
line distributors.
For more information on Retractable, visit its
website at www.retractable.com.
Forward-looking statements in this press release
are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current
views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate.
However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from
such statements.
Factors that could cause or contribute to such
differences include, but are not limited to: tariffs; material changes in demand, Retractable's ability to maintain liquidity; Retractable's
maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and
relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in
providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic
reports filed with the U.S. Securities and Exchange Commission.
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief
Accounting Officer
